HemoShear Therapeutics Names Robert Gould to Board of Directors
Friday, July 17, 2015
HemoShear Therapeutics, a privately held discovery stage biotechnology company appointed Robert J. Gould, Ph.D., President and CEO of Epizyme, Inc., to the HemoShear Therapeutics Board of Directors. Dr. Gould brings more than 30 years of experience in the pharmaceutical and biotechnology industry.
"Robert is a respected leader with an extensive background in drug discovery and will be invaluable to us as we advance our current proprietary drug discovery programs in rare metabolic disorders and non-alcoholic steatohepatitis (NASH), as well as expand our future pipeline," said Jim Powers, Chairman and CEO of HemoShear Therapeutics. "The exceptional insights he has gained at Epizyme, the Broad Institute, and Merck will be a critical asset as we apply our deep understanding of human disease biology through our transformational disease models and advanced in silico computational capabilities."
Dr. Gould joined the Board of Epizyme in 2008 and became President and CEO in 2010. He has guided Epizyme's growth and development into a clinical stage biopharmaceutical company, developing novel epigenetic therapies for cancer patients. Under his leadership, the company established significant collaborations with Celgene, GSK and Eisai, and completed a successful initial public offering in 2013. Previously, Dr. Gould was Director of Novel Therapeutics at The Broad Institute of MIT and Harvard. Before joining the Broad, Dr. Gould spent 23 years at Merck & Co., Inc., where he held a variety of leadership positions, including Vice President of Licensing and External Research and Vice President of Basic Research at Merck Research Laboratories. Dr. Gould received a B.A. in chemistry from Spring Arbor College, and a Ph.D. in biochemistry from The University of Iowa and undertook post-doctoral studies at The Johns Hopkins University.
"I have been following HemoShear's progress for several years," said Dr. Gould. "They have a unique ability to model and interpret disease biology that allows them to deeply interrogate underlying mechanisms and pathophysiology. There is a clear recognition in our industry that we need better fundamental models of disease. I believe their platform has tremendous potential to build a portfolio of novel drug targets and drug candidates leading to important therapies for patients with high unmet need. I look forward to working with the team to help HemoShear realize their mission to profoundly impact human health."